Data from multiple sources - Curated by Toby Galbraith - Last updated 04 July 2017

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) comprises a heterogenous group of lymphoid tissue tumours, distinguished from Hodgkin’s lymphoma by their absence of Reed-Sternberg cells on ...

Read more on Non-Hodgkin lymphoma


Latest news articles

Added 17 days ago Drug news

FDA accepts for review the BLA for CT P10 biosimilar to Rituxan (rituximab).- Teva + Celltrion

Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted for review the...

Added 21 days ago Drug news

FDA grants market authorization of ClearL Lab Reagents (T1, T2, B1, B2, M) to Beckman Coulter, aid in the detection of leukemias and lymphomas.

The FDA has granted market authorization of ClearLLab Reagents (T1, T2, B1, B2, M) to Beckman Coulter, Inc. The allowed...

Added 1 month ago Drug news

Interim analysis of MAGNIFY phase IIIb study of Revlimid (lenalidomide) plus rituximab in marginal zone lymphoma- Celgene Corp

Celgene Corporation announced results from an interim analysis of MAGNIFY, a phase IIIb, randomized, open-label, multicenter study of Revlimid (lenalidomide)...

Search all news articles for Non-Hodgkin lymphoma

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)


Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

Visit Hyperammonaemia


ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 9 months ago

Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines

Follicular lymphomas are the second most frequent subtype of nodal lymphoid malignancies in Western Europe. The annual incidence of this disease is rare but has increased during recent decades.

Added 9 months ago

Extranodal Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma: ESMO Clinical Practice Guidelines

Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. Most DLBCLs originate in lymph nodes, but ≤40% initially present in extranodal sites.

Added 9 months ago

Search all guidelines for Non-Hodgkin lymphoma

Journal articles

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group.

To study pharmacokinetics, toxicity, and efficacy of prolonged rituximab exposure in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Added 1 month ago

Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.

Interval reduction from 3 (CHOP-21) to 2 wks (CHOP-14) and the addition of R to CHOP-21 (R-CHOP-21) improved outcome in elderly pts with DLBCL to a similar extent compared to CHOP-21.

Added 1 month ago

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Ho’gkin’s lymphoma.

High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses.

Added 1 month ago

Search all journal articles for Non-Hodgkin lymphoma

Clinical trials

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma...

Added 1 month ago

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms...

Added 9 months ago

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator...

Added 1 month ago

Search all clinical trials for Non-Hodgkin lymphoma
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.


Night sweats - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
Registration required
Subscription fee
Search all CME for Non-Hodgkin lymphoma